Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2022 · 10-Q
Revenue$206.00K$206.00K−41.1% vs Q3 2021 Net Income-$32.85M-$32.85MN/M vs Q3 2021 EPS Diluted-$0.03-$0.03N/M vs Q3 2021 Operating Income-$15,618,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-7581.6%−4710.4 pt vs Q3 2021
Net margin-15947.6%
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end